Promega Expands Oncology Diagnostics Portfolio with FDA-Approved MSI Companion Diagnostic
Event summary
- Promega showcases new oncology research tools and companion diagnostics at AACR Annual Meeting 2026, April 17-22.
- FDA and NMPA approval for Promega OncoMate® MSI Dx Analysis System marks regulatory milestone.
- Company introduces TarSeer™ BRETSA™ Target Engagement System for drug discovery workflows.
- Promega unveils red-shifted NanoPrism™ luciferase for two-color bioluminescence analyses.
The big picture
Promega's expansion into FDA-approved companion diagnostics represents a strategic pivot toward higher-value clinical applications, complementing its core life science tools business. The company is positioning itself at the intersection of oncology research and precision medicine, where regulatory approvals can drive significant market differentiation.
What we're watching
- Regulatory Momentum
- Whether Promega can leverage FDA and NMPA approvals to accelerate global adoption of its MSI companion diagnostic.
- Market Differentiation
- How TarSeer™ BRETSA™ system will position Promega in the competitive drug discovery tools market.
- Technological Integration
- The pace at which Promega can commercialize its red-shifted NanoPrism™ luciferase for broader research applications.
Related topics